ERBB2 and breast carcinoma: In the present study, seven HER2-positive patients had somatic mutations in PIK3CA. The great majority of patients with actionable mutations in our Clinseq study had alterations in genes matching breast cancer studies in early phase, 146 (48%), while 16 (5%) were matched with studies in late phase (Fig. 4B).